Pro-Calcifying Role of Enzymatically Modified LDL (eLDL) in Aortic Valve Sclerosis via Induction of IL-6 and IL-33

One of the contributors to atherogenesis is enzymatically modified LDL (eLDL). eLDL was detected in all stages of aortic valve sclerosis and was demonstrated to trigger the activation of p38 mitogen-activated protein kinase (p38 MAPK), which has been identified as a pro-inflammatory protein in atherosclerosis. In this study, we investigated the influence of eLDL on IL-6 and IL-33 induction, and also the impact of eLDL on calcification in aortic valve stenosis (AS). eLDL upregulated phosphate-induced calcification in valvular interstitial cells (VICs)/myofibroblasts isolated from diseased aortic valves, as demonstrated by alizarin red staining. Functional studies demonstrated activation of p38 MAPK as well as an altered gene expression of osteogenic genes known to be involved in vascular calcification. In parallel with the activation of p38 MAPK, eLDL also induced upregulation of the cytokines IL-6 and IL-33. The results suggest a pro-calcifying role of eLDL in AS via induction of IL-6 and IL-33.

[1]  D. Tousoulis,et al.  The Impact of Cytokines in Coronary Atherosclerotic Plaque: Current Therapeutic Approaches , 2022, International journal of molecular sciences.

[2]  María Martín,et al.  IL6 gene polymorphism association with calcific aortic valve stenosis and influence on serum levels of interleukin-6 , 2022, Frontiers in Cardiovascular Medicine.

[3]  E. Emmanouil,et al.  Deletion of the Pyrophosphate Generating Enzyme ENPP1 Rescues Craniofacial Abnormalities in the TNAP−/− Mouse Model of Hypophosphatasia and Reveals FGF23 as a Marker of Phenotype Severity , 2022, Frontiers in Dental Medicine.

[4]  M. Pesce,et al.  The Complex Interplay of Inflammation, Metabolism, Epigenetics, and Sex in Calcific Disease of the Aortic Valve , 2022, Frontiers in Cardiovascular Medicine.

[5]  S. Kersten.  Role and mechanism of the action of angiopoietin-like protein ANGPTL4 in plasma lipid metabolism , 2021, Journal of lipid research.

[6]  M. Torzewski.  The Initial Human Atherosclerotic Lesion and Lipoprotein Modification—A Deep Connection , 2021, International journal of molecular sciences.

[7]  Xiaoqiong Gu,et al.  Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML , 2020, Frontiers in Immunology.

[8]  Jiawei Shi,et al.  Inhibition of PP2A enhances the osteogenic differentiation of human aortic valvular interstitial cells via ERK and p38 MAPK pathways. , 2020, Life sciences.

[9]  U. Landmesser,et al.  Calcific Aortic Valve Disease-Natural History and Future Therapeutic Strategies , 2020, Frontiers in Pharmacology.

[10]  S. Zimmer,et al.  Aortic Valve Stenosis , 2020, Arteriosclerosis, thrombosis, and vascular biology.

[11]  M. Gaestel,et al.  p38 MAPK signalling regulates cytokine production in IL-33 stimulated Type 2 Innate Lymphoid cells , 2020, Scientific Reports.

[12]  M. Borchers,et al.  IL‐33 promotes type 1 cytokine expression via p38 MAPK in human NK cells , 2020, Journal of leukocyte biology.

[13]  M. Dweck,et al.  Pathophysiology of Aortic Stenosis and Future Perspectives for Medical Therapy. , 2020, Cardiology clinics.

[14]  Li-Ming Lu,et al.  IL-33 promotes the progression of nonrheumatic aortic valve stenosis via inducing differential phenotypic transition in valvular interstitial cells. , 2019, Journal of cardiology.

[15]  D. Ramji,et al.  The interleukin-33-mediated inhibition of expression of two key genes implicated in atherosclerosis in human macrophages requires MAP kinase, phosphoinositide 3-kinase and nuclear factor-κB signaling pathways , 2019, Scientific Reports.

[16]  Dong Wang,et al.  MicroRNA‐638 inhibits human aortic valve interstitial cell calcification by targeting Sp7 , 2019, Journal of cellular and molecular medicine.

[17]  M. Torzewski,et al.  Role of p38 MAPK in Atherosclerosis and Aortic Valve Sclerosis , 2018, International journal of molecular sciences.

[18]  Chunling Zhang,et al.  Enzyme-modified non-oxidized LDL (ELDL) induces human coronary artery smooth muscle cell transformation to a migratory and osteoblast-like phenotype , 2018, Scientific Reports.

[19]  Joshua D. Hutcheson,et al.  Spatiotemporal Multi-Omics Mapping Generates a Molecular Atlas of the Aortic Valve and Reveals Networks Driving Disease , 2018, Circulation.

[20]  T. Imaizumi,et al.  Matrix Gla protein negatively regulates calcification of human aortic valve interstitial cells isolated from calcified aortic valves. , 2018, Journal of pharmacological sciences.

[21]  S. Laufer,et al.  Selective p38α MAP kinase/MAPK14 inhibition in enzymatically modified LDL‐stimulated human monocytes: implications for atherosclerosis , 2017, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[22]  F. Liew,et al.  Interleukin-33 in health and disease , 2016, Nature Reviews Immunology.

[23]  Z. Cao,et al.  Role of Osterix and MicroRNAs in Bone Formation and Tooth Development , 2016, Medical science monitor : international medical journal of experimental and clinical research.

[24]  C. Ramírez,et al.  ANGPTL4 deficiency in haematopoietic cells promotes monocyte expansion and atherosclerosis progression , 2016, Nature Communications.

[25]  T. Arnett,et al.  Pyrophosphate: a key inhibitor of mineralisation. , 2016, Current opinion in pharmacology.

[26]  G. Ferns,et al.  Increased expression of phosphorylated forms of heat‐shock protein‐27 and p38MAPK in macrophage‐rich regions of fibro‐fatty atherosclerotic lesions in the rabbit , 2016, International journal of experimental pathology.

[27]  U. Hofmann,et al.  Enzymatically Modified Low‐Density Lipoprotein Is Present in All Stages of Aortic Valve Sclerosis: Implications for Pathogenesis of the Disease , 2015, Journal of the American Heart Association.

[28]  M. Dweck,et al.  Calcification in Aortic Stenosis: The Skeleton Key. , 2015, Journal of the American College of Cardiology.

[29]  Cong-Lin Liu,et al.  Characterization of interleukin-33 and matrix metalloproteinase-28 in serum and their association with disease severity in patients with coronary heart disease , 2014, Coronary artery disease.

[30]  Y. Bossé,et al.  P2Y2 receptor represses IL-6 expression by valve interstitial cells through Akt: implication for calcific aortic valve disease. , 2014, Journal of molecular and cellular cardiology.

[31]  Thoralf M Sundt,et al.  2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Journal of the American College of Cardiology.

[32]  A. Zernecke,et al.  Chemokines in Atherosclerosis: Proceedings Resumed , 2014, Arteriosclerosis, thrombosis, and vascular biology.

[33]  P. He,et al.  MAPK-PPARα/γ signal transduction pathways are involved in Chlamydia pneumoniae-induced macrophage-derived foam cell formation. , 2014, Microbial pathogenesis.

[34]  N. Xu,et al.  β-Glucan attenuates inflammatory responses in oxidized LDL-induced THP-1 cells via the p38 MAPK pathway. , 2014, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[35]  S. Body,et al.  Calcific aortic valve disease: a consensus summary from the Alliance of Investigators on Calcific Aortic Valve Disease. , 2013, Arteriosclerosis, thrombosis, and vascular biology.

[36]  M. Dweck,et al.  Calcific aortic stenosis: a disease of the valve and the myocardium. , 2012, Journal of the American College of Cardiology.

[37]  W. Carver,et al.  Effects of interleukin-33 on cardiac fibroblast gene expression and activity. , 2012, Cytokine.

[38]  E. McNally,et al.  Genetic pathways of vascular calcification. , 2012, Trends in cardiovascular medicine.

[39]  Zhenqi Liu,et al.  p38 Mitogen-activated Protein Kinase (MAPK) Promotes Cholesterol Ester Accumulation in Macrophages through Inhibition of Macroautophagy* , 2012, The Journal of Biological Chemistry.

[40]  K. J. Grande-Allen,et al.  Calcific Aortic Valve Disease : Not Simply a Degenerative Process A Review and Agenda for Research from the National Heart and Lung and Blood Institute Aortic Stenosis Working Group , 2012 .

[41]  E. Aikawa,et al.  Molecular Imaging Insights Into Early Inflammatory Stages of Arterial and Aortic Valve Calcification , 2011, Circulation research.

[42]  R. Weiss,et al.  Calcific Aortic Valve Stenosis: Methods, Models, and Mechanisms , 2011, Circulation research.

[43]  R. Hinton,et al.  Differential expression of cartilage and bone-related proteins in pediatric and adult diseased aortic valves. , 2011, Journal of molecular and cellular cardiology.

[44]  Ashley M. Miller,et al.  IL-33 Reduces Macrophage Foam Cell Formation , 2010, The Journal of Immunology.

[45]  S. Kersten,et al.  Induction of Cardiac Angptl4 by Dietary Fatty Acids Is Mediated by Peroxisome Proliferator-Activated Receptor &bgr;/&dgr; and Protects Against Fatty Acid–Induced Oxidative Stress , 2010, Circulation research.

[46]  G. Dubyak,et al.  Regulation of vascular smooth muscle cell calcification by extracellular pyrophosphate homeostasis: synergistic modulation by cyclic AMP and hyperphosphatemia. , 2010, American journal of physiology. Cell physiology.

[47]  H. Hendriks,et al.  Caloric Restriction and Exercise Increase Plasma ANGPTL4 Levels in Humans via Elevated Free Fatty Acids , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[48]  K. Masters,et al.  Role of the MAPK/ERK pathway in valvular interstitial cell calcification. , 2009, American journal of physiology. Heart and circulatory physiology.

[49]  F. Schick,et al.  Muscle-Derived Angiopoietin-Like Protein 4 Is Induced by Fatty Acids via Peroxisome Proliferator–Activated Receptor (PPAR)-δ and Is of Metabolic Relevance in Humans , 2009, Diabetes.

[50]  L. Schurgers,et al.  Matrix Gla-protein: The calcification inhibitor in need of vitamin K , 2008, Thrombosis and Haemostasis.

[51]  D. Crossman,et al.  LDL uptake by monocytes in response to inflammation is MAPK dependent but independent of tribbles protein expression. , 2008, Immunology letters.

[52]  Ashley M. Miller,et al.  IL-33 reduces the development of atherosclerosis , 2008, The Journal of experimental medicine.

[53]  Timur Shtatland,et al.  Osteogenesis Associates With Inflammation in Early-Stage Atherosclerosis Evaluated by Molecular Imaging In Vivo , 2007, Circulation.

[54]  Ralph Weissleder,et al.  Multimodality Molecular Imaging Identifies Proteolytic and Osteogenic Activities in Early Aortic Valve Disease , 2007, Circulation.

[55]  P. Kovanen,et al.  Low-Density Lipoprotein Modified by Macrophage-Derived Lysosomal Hydrolases Induces Expression and Secretion of IL-8 Via p38 MAPK and NF-&kgr;B by Human Monocyte-Derived Macrophages , 2006 .

[56]  C. Shanahan,et al.  Molecular mechanisms mediating vascular calcification: Role of matrix Gla protein (Review Article) , 2006, Nephrology.

[57]  J. Gardin,et al.  Burden of valvular heart diseases: a population-based study , 2006, The Lancet.

[58]  J Fernando Bazan,et al.  IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. , 2005, Immunity.

[59]  H. Ichijo,et al.  Fatty acids liberated from low-density lipoprotein trigger endothelial apoptosis via mitogen-activated protein kinases , 2005, Cell Death and Differentiation.

[60]  R. Terkeltaub,et al.  The mutational spectrum of ENPP1 as arising after the analysis of 23 unrelated patients with generalized arterial calcification of infancy (GACI) , 2005, Human mutation.

[61]  K. Lackner,et al.  Enzymatic Modification of Low-Density Lipoprotein in the Arterial Wall: A New Role for Plasmin and Matrix Metalloproteinases in Atherogenesis , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[62]  Prapat Suriyaphol,et al.  Possible Protective Role for C-Reactive Protein in Atherogenesis: Complement Activation by Modified Lipoproteins Halts Before Detrimental Terminal Sequence , 2004, Circulation.

[63]  K. Lackner,et al.  Beyond cholesterol: the enigma of atherosclerosis revisited , 2004, Thrombosis and Haemostasis.

[64]  J. Boehm,et al.  p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases , 2003, Nature Reviews Drug Discovery.

[65]  R. Terkeltaub,et al.  Mutations in ENPP1 are associated with 'idiopathic' infantile arterial calcification , 2003, Nature Genetics.

[66]  Philippe Ravaud,et al.  A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease. , 2003, European heart journal.

[67]  A. Tajik,et al.  Human Aortic Valve Calcification Is Associated With an Osteoblast Phenotype , 2003, Circulation.

[68]  Kenichi Yoshida,et al.  Angiopoietin-like protein 4 is a potent hyperlipidemia-inducing factor in mice and inhibitor of lipoprotein lipase Published, JLR Papers in Press, September 16, 2002. DOI 10.1194/jlr.C200010-JLR200 , 2002, Journal of Lipid Research.

[69]  R. Terkeltaub,et al.  Tissue-nonspecific alkaline phosphatase and plasma cell membrane glycoprotein-1 are central antagonistic regulators of bone mineralization , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[70]  Jiahuai Han,et al.  Activation of the p38 MAP kinase pathway is required for foam cell formation from macrophages exposed to oxidized LDL , 2002, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[71]  J. Deng,et al.  The Novel Zinc Finger-Containing Transcription Factor Osterix Is Required for Osteoblast Differentiation and Bone Formation , 2002, Cell.

[72]  E. Hawe,et al.  The interleukin-6 -174 G/C promoter polymorphism is associated with risk of coronary heart disease and systolic blood pressure in healthy men. , 2001, European heart journal.

[73]  S. Chien,et al.  LDL-Activated p38 in Endothelial Cells Is Mediated by Ras , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[74]  P. Schauerte,et al.  PC-1 nucleoside triphosphate pyrophosphohydrolase deficiency in idiopathic infantile arterial calcification. , 2001, The American journal of pathology.

[75]  H. Gabbert,et al.  Immunohistochemical demonstration of enzymatically modified human LDL and its colocalization with the terminal complement complex in the early atherosclerotic lesion. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[76]  S. Bhakdi,et al.  On the pathogenesis of atherosclerosis: enzymatic transformation of human low density lipoprotein to an atherogenic moiety , 1995, The Journal of experimental medicine.

[77]  T. Mosmann.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.

[78]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[79]  R. H. Eaton,et al.  Organic pyrophosphates as substrates for human alkaline phosphatases. , 1967, The Biochemical journal.

[80]  M. Torzewski.  Enzymatically modified LDL, atherosclerosis and beyond: paving the way to acceptance. , 2018, Frontiers in bioscience.

[81]  J. Cleveland,et al.  Expression of functional Toll-like receptors 2 and 4 in human aortic valve interstitial cells: potential roles in aortic valve inflammation and stenosis. , 2008, American journal of physiology. Cell physiology.

[82]  B. Warren,et al.  Calcification of the aortic valve: Its progression and grading , 1997, Pathology.

[83]  L. Ryan,et al.  Inorganic pyrophosphate metabolism in arthritis. , 1988, Rheumatic diseases clinics of North America.